KR100829674B1 - 단당류 또는 이당류계 화합물을 이용한 전염성 및 다른질병의 예방 및 치료 방법 - Google Patents
단당류 또는 이당류계 화합물을 이용한 전염성 및 다른질병의 예방 및 치료 방법 Download PDFInfo
- Publication number
- KR100829674B1 KR100829674B1 KR1020027015626A KR20027015626A KR100829674B1 KR 100829674 B1 KR100829674 B1 KR 100829674B1 KR 1020027015626 A KR1020027015626 A KR 1020027015626A KR 20027015626 A KR20027015626 A KR 20027015626A KR 100829674 B1 KR100829674 B1 KR 100829674B1
- Authority
- KR
- South Korea
- Prior art keywords
- pharmaceutical composition
- group
- independently selected
- subject
- acyl groups
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H13/00—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids
- C07H13/02—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids
- C07H13/04—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids having the esterifying carboxyl radicals attached to acyclic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7024—Esters of saccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H11/00—Compounds containing saccharide radicals esterified by inorganic acids; Metal salts thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H13/00—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids
- C07H13/02—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids
- C07H13/04—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids having the esterifying carboxyl radicals attached to acyclic carbon atoms
- C07H13/06—Fatty acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/02—Acyclic radicals, not substituted by cyclic structures
- C07H15/14—Acyclic radicals, not substituted by cyclic structures attached to a sulfur, selenium or tellurium atom of a saccharide radical
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Pulmonology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Neurosurgery (AREA)
- Tropical Medicine & Parasitology (AREA)
- Neurology (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Hospice & Palliative Care (AREA)
- AIDS & HIV (AREA)
- Pain & Pain Management (AREA)
- Transplantation (AREA)
- Psychiatry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Otolaryngology (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US20582000P | 2000-05-19 | 2000-05-19 | |
| US60/205,820 | 2000-05-19 | ||
| US28156701P | 2001-04-04 | 2001-04-04 | |
| US60/281,567 | 2001-04-04 | ||
| PCT/US2001/016327 WO2001090129A2 (en) | 2000-05-19 | 2001-05-18 | Prophylactic and therapeutic treatment of infectious, autoimmune and allergic diseases with mono and disaccharide-base compounds |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20030031485A KR20030031485A (ko) | 2003-04-21 |
| KR100829674B1 true KR100829674B1 (ko) | 2008-05-16 |
Family
ID=26900794
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020027015626A Expired - Lifetime KR100829674B1 (ko) | 2000-05-19 | 2001-05-18 | 단당류 또는 이당류계 화합물을 이용한 전염성 및 다른질병의 예방 및 치료 방법 |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US6800613B2 (cg-RX-API-DMAC7.html) |
| EP (2) | EP2000144A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP5004261B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR100829674B1 (cg-RX-API-DMAC7.html) |
| CN (1) | CN1606446A (cg-RX-API-DMAC7.html) |
| AT (1) | ATE395923T1 (cg-RX-API-DMAC7.html) |
| AU (3) | AU2001269695B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BR0110975A (cg-RX-API-DMAC7.html) |
| CA (1) | CA2409221C (cg-RX-API-DMAC7.html) |
| CY (1) | CY1108211T1 (cg-RX-API-DMAC7.html) |
| DE (1) | DE60134134D1 (cg-RX-API-DMAC7.html) |
| DK (1) | DK1284740T3 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2305086T3 (cg-RX-API-DMAC7.html) |
| HU (1) | HU230847B1 (cg-RX-API-DMAC7.html) |
| IL (3) | IL152935A0 (cg-RX-API-DMAC7.html) |
| MX (1) | MXPA02011486A (cg-RX-API-DMAC7.html) |
| NO (1) | NO331939B1 (cg-RX-API-DMAC7.html) |
| NZ (1) | NZ522755A (cg-RX-API-DMAC7.html) |
| PL (1) | PL206832B1 (cg-RX-API-DMAC7.html) |
| PT (1) | PT1284740E (cg-RX-API-DMAC7.html) |
| WO (1) | WO2001090129A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (82)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6835721B2 (en) | 1999-02-01 | 2004-12-28 | Eisai Co., Ltd. | Immunomodulatory compounds and methods of use thereof |
| US20040006242A1 (en) * | 1999-02-01 | 2004-01-08 | Hawkins Lynn D. | Immunomodulatory compounds and method of use thereof |
| US7915238B2 (en) | 1999-02-01 | 2011-03-29 | Eisai R & D Management Co., Ltd. | Immunomodulatory compounds and methods of use thereof |
| US20030105032A1 (en) * | 2000-05-19 | 2003-06-05 | Persing David H. | Phophylactic and therapeutic treatment of infectious and other diseases with mono-and disaccharide-based compounds |
| EP1435987A4 (en) * | 2001-09-07 | 2005-11-23 | Univ Boston | METHOD AND COMPOSITION FOR THE TREATMENT OF DISEASES RELATED TO THE IMMUNO COMPLEX |
| EP1302206A1 (en) * | 2001-10-11 | 2003-04-16 | Universitair Medisch Centrum Utrecht | Methods and means for the use of the adventitial toll-like receptor |
| IL163305A (en) * | 2002-02-04 | 2010-10-31 | Corixa Corp | Azacycloalkyl glucosaminide phosphate as immunoeffector compounds and pharmaceutical compositions for propylactic and therapeutic treatment of infectious and therapeutic treatment of infectious and other diseases comprising the same |
| US6911434B2 (en) | 2002-02-04 | 2005-06-28 | Corixa Corporation | Prophylactic and therapeutic treatment of infectious and other diseases with immunoeffector compounds |
| NZ537655A (en) | 2002-07-08 | 2006-12-22 | Corixa Corp | Processes for the production of aminoalkyl glucosaminide phosphate and disaccharide immunoeffectors, and intermediates therefor |
| SI1589934T1 (sl) | 2003-01-06 | 2016-02-29 | Corixa Corporation Corporation Service Company | Določene aminoalkil glukozaminid fosfat spojine in njih uporaba |
| US7960522B2 (en) | 2003-01-06 | 2011-06-14 | Corixa Corporation | Certain aminoalkyl glucosaminide phosphate compounds and their use |
| US20060263778A1 (en) * | 2004-03-05 | 2006-11-23 | Johnson Geoffrey B | Animals with reduced body fat and increased bone density |
| EP1848993A1 (en) | 2005-01-27 | 2007-10-31 | Novartis Vaccines and Diagnostics, Inc. | A method for characterizing the efficacy of an agent targeting a primary cystic fibrosis defect |
| CN101355928B (zh) | 2005-04-26 | 2013-05-22 | 卫材R&D管理株式会社 | 用于癌症免疫疗法的组合物和方法 |
| GB0510463D0 (en) * | 2005-05-23 | 2005-06-29 | Britania Pharmaceuticals Ltd | Improvements in or relating to organic materials |
| US7622128B2 (en) * | 2005-12-13 | 2009-11-24 | University Of Washington | Porphyromonas gingivalis 1435/1449 LPS as an immune modulator |
| EP2468300B1 (en) | 2006-09-26 | 2017-12-20 | Infectious Disease Research Institute | Vaccine composition containing synthetic adjuvant |
| US20090181078A1 (en) * | 2006-09-26 | 2009-07-16 | Infectious Disease Research Institute | Vaccine composition containing synthetic adjuvant |
| US20090215710A1 (en) * | 2007-09-24 | 2009-08-27 | Reliance Life Sciences Pvt. Ltd. | Carbohydrate based toll-like receptor (tlr) antagonists |
| EP2214692A2 (en) * | 2007-10-31 | 2010-08-11 | Centocor Ortho Biotech Inc. | Use of toll-like receptor 4 antagonists for the treatment or prevention of osteoarthritic conditions |
| CA2764374C (en) | 2009-06-05 | 2019-11-19 | Infectious Disease Research Institute | Synthetic glucopyranosyl lipid adjuvants |
| WO2011119920A2 (en) | 2010-03-25 | 2011-09-29 | Oregon Health & Science University | Cmv glycoproteins and recombinant vectors |
| CA2811957C (en) | 2010-09-22 | 2019-04-16 | The University Of Melbourne | Soluble tlr2 moiety for use in the treatment or prevention of respiratory conditions associated with infectious agents |
| GB201101331D0 (en) | 2011-01-26 | 2011-03-09 | Glaxosmithkline Biolog Sa | Compositions and uses |
| ES2667425T3 (es) | 2011-06-10 | 2018-05-10 | Oregon Health & Science University | Glucoproteínas y vectores recombinantes de CMV |
| GB201113570D0 (en) | 2011-08-05 | 2011-09-21 | Glaxosmithkline Biolog Sa | Vaccine |
| AU2012216792A1 (en) | 2011-09-12 | 2013-03-28 | International Aids Vaccine Initiative | Immunoselection of recombinant vesicular stomatitis virus expressing HIV-1 proteins by broadly neutralizing antibodies |
| EP2586461A1 (en) | 2011-10-27 | 2013-05-01 | Christopher L. Parks | Viral particles derived from an enveloped virus |
| US9241988B2 (en) * | 2012-04-12 | 2016-01-26 | Avanti Polar Lipids, Inc. | Disaccharide synthetic lipid compounds and uses thereof |
| SMT201800368T1 (it) | 2012-05-16 | 2018-09-13 | Immune Design Corp | Vaccini per l'infezione da virus-2 herpes simplex |
| EP2679596B1 (en) | 2012-06-27 | 2017-04-12 | International Aids Vaccine Initiative | HIV-1 env glycoprotein variant |
| WO2014141127A1 (en) | 2013-03-15 | 2014-09-18 | Glaxosmithkline Biologicals S.A. | Composition containing buffered aminoalkyl glucosaminide phosphate derivatives and its use for enhancing an immune response |
| CA2909221A1 (en) | 2013-04-18 | 2014-10-23 | Immune Design Corp. | Gla monotherapy for use in cancer treatment |
| US9463198B2 (en) | 2013-06-04 | 2016-10-11 | Infectious Disease Research Institute | Compositions and methods for reducing or preventing metastasis |
| US20150065381A1 (en) | 2013-09-05 | 2015-03-05 | International Aids Vaccine Initiative | Methods of identifying novel hiv-1 immunogens |
| EP2873423B1 (en) | 2013-10-07 | 2017-05-31 | International Aids Vaccine Initiative | Soluble hiv-1 envelope glycoprotein trimers |
| AU2015228387A1 (en) | 2014-03-12 | 2016-10-27 | Glaxosmithkline Biologicals S.A. | Immunogenic liposomal formulation |
| CN106456546A (zh) | 2014-03-12 | 2017-02-22 | 葛兰素史密丝克莱恩生物有限公司 | 用于黏膜递送的脂质体组合物 |
| MA41414A (fr) | 2015-01-28 | 2017-12-05 | Centre Nat Rech Scient | Protéines de liaison agonistes d' icos |
| US10174292B2 (en) | 2015-03-20 | 2019-01-08 | International Aids Vaccine Initiative | Soluble HIV-1 envelope glycoprotein trimers |
| EP3072901A1 (en) | 2015-03-23 | 2016-09-28 | International Aids Vaccine Initiative | Soluble hiv-1 envelope glycoprotein trimers |
| WO2017013603A1 (en) | 2015-07-21 | 2017-01-26 | Glaxosmithkline Biologicals Sa | Adjuntive immunotherapy for the prevention or treatment of infectious disease |
| TW201716084A (zh) | 2015-08-06 | 2017-05-16 | 葛蘭素史克智慧財產發展有限公司 | 組合物及其用途與治療 |
| BR112018002520A2 (pt) | 2015-08-06 | 2018-09-18 | Glaxosmithkline Ip Dev Ltd | Agonistas de tlr4 e composições dos mesmos e seuuso no tratamento de câncer |
| WO2017021912A1 (en) | 2015-08-06 | 2017-02-09 | Glaxosmithkline Intellectual Property Development Limited | Combined tlrs modulators with anti ox40 antibodies |
| JP6411676B2 (ja) | 2015-12-03 | 2018-10-24 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドGlaxosmithkline Intellectual Property Development Limited | Stingの調節因子としての環状プリンジヌクレオチド |
| WO2017098421A1 (en) | 2015-12-08 | 2017-06-15 | Glaxosmithkline Intellectual Property Development Limited | Benzothiadiazine compounds |
| WO2017153952A1 (en) | 2016-03-10 | 2017-09-14 | Glaxosmithkline Intellectual Property Development Limited | 5-sulfamoyl-2-hydroxybenzamide derivatives |
| WO2017175156A1 (en) | 2016-04-07 | 2017-10-12 | Glaxosmithkline Intellectual Property Development Limited | Heterocyclic amides useful as protein modulators |
| SG10201900628RA (en) | 2016-04-07 | 2019-02-27 | Glaxosmithkline Ip Dev Ltd | Heterocyclic amides useful as protein modulators |
| WO2017191545A1 (en) | 2016-05-05 | 2017-11-09 | Glaxosmithkline Intellectual Property (No.2) Limited | Enhancer of zeste homolog 2 inhibitors |
| CN109789135A (zh) | 2016-07-20 | 2019-05-21 | 葛兰素史密斯克莱知识产权发展有限公司 | 作为perk抑制剂的异喹啉衍生物 |
| CN110225983A (zh) | 2016-12-01 | 2019-09-10 | 葛兰素史密斯克莱知识产权发展有限公司 | 治疗癌症的方法 |
| WO2018204302A1 (en) | 2017-05-01 | 2018-11-08 | Vanderbilt University | Phosphorylated hexaacyl disaccharides (phads) for treating or preventing infections |
| WO2019021208A1 (en) | 2017-07-27 | 2019-01-31 | Glaxosmithkline Intellectual Property Development Limited | USEFUL INDAZOLE DERIVATIVES AS PERK INHIBITORS |
| WO2019053617A1 (en) | 2017-09-12 | 2019-03-21 | Glaxosmithkline Intellectual Property Development Limited | CHEMICAL COMPOUNDS |
| US11377440B2 (en) | 2017-10-05 | 2022-07-05 | Glaxosmithkline Intellectual Property Development Limited | Modulators of stimulator of interferon genes (STING) |
| AU2018344902B2 (en) | 2017-10-05 | 2021-06-03 | Glaxosmithkline Intellectual Property Development Limited | Modulators of stimulator of interferon genes (STING) useful in treating HIV |
| IL275360B2 (en) | 2017-12-21 | 2023-10-01 | Axelia Oncology Pty Ltd | Optimal compounds |
| BR112020016314A2 (pt) | 2018-02-12 | 2020-12-15 | Inimmune Corporation | Compostos ou um sais farmaceuticamente aceitáveis, composição farmacêutica, kit, e, métodos para elicitar, intensificar ou modificar uma resposta imunológica, para tratar, prevenir ou reduzir a suscetibilidade a câncer, para tratar, prevenir ou reduzir a suscetibilidade a uma doença infecciosa, para tratar, prevenir ou reduzir a suscetibilidade a uma alergia, para tratar, prevenir ou reduzir a suscetibilidade a uma afecção autoimune, para tratar, prevenir ou reduzir a suscetibilidade em um sujeito à infecção bacteriana, viral, priônica, autoimunidade, câncer ou alergia, para tratar, prevenir ou reduzir a suscetibilidade à autoimunidade, alergia, reperfusão de isquemia ou sepse, para tratar, prevenir ou reduzir a gravidade de ataques epiléticos e para tratar, prevenir ou reduzir a suscetibilidade a doenças oculares como degeneração macular, hipertensão ocular e infecção ocular |
| GB201807924D0 (en) | 2018-05-16 | 2018-06-27 | Ctxt Pty Ltd | Compounds |
| WO2020031087A1 (en) | 2018-08-06 | 2020-02-13 | Glaxosmithkline Intellectual Property Development Limited | Combination therapy |
| WO2020030571A1 (en) | 2018-08-06 | 2020-02-13 | Glaxosmithkline Intellectual Property Development Limited | Combinations of a pd-1 antibody and a tlr4 modulator and uses thereof |
| WO2020030570A1 (en) | 2018-08-06 | 2020-02-13 | Glaxosmithkline Intellectual Property Development Limited | Combinations of an ox40 antibody and a tlr4 modulator and uses thereof |
| EP3886901A1 (en) | 2018-11-29 | 2021-10-06 | GlaxoSmithKline Biologicals S.A. | Methods for manufacturing an adjuvant |
| CA3143211A1 (en) | 2019-06-26 | 2020-12-30 | Glaxosmithkline Intellectual Property Development Limited | Il1rap binding proteins |
| NZ783377A (en) | 2019-06-26 | 2026-03-27 | Ena Respiratory Pty Ltd | Pegylated novel molecules for agonising tlr2 |
| GB201910304D0 (en) | 2019-07-18 | 2019-09-04 | Ctxt Pty Ltd | Compounds |
| GB201910305D0 (en) | 2019-07-18 | 2019-09-04 | Ctxt Pty Ltd | Compounds |
| MX2022000879A (es) | 2019-07-21 | 2022-05-02 | Glaxosmithkline Biologicals Sa | Vacuna viral terapeutica. |
| WO2021018941A1 (en) | 2019-07-31 | 2021-02-04 | Glaxosmithkline Intellectual Property Development Limited | Methods of treating cancer |
| WO2021043961A1 (en) | 2019-09-06 | 2021-03-11 | Glaxosmithkline Intellectual Property Development Limited | Dosing regimen for the treatment of cancer with an anti icos agonistic antibody and chemotherapy |
| CN114466659A (zh) | 2019-09-09 | 2022-05-10 | 葛兰素史克生物有限公司 | 免疫治疗组合物 |
| AU2020355614B2 (en) | 2019-09-27 | 2024-12-05 | Glaxosmithkline Intellectual Property Development Limited | Antigen binding proteins |
| WO2021119753A1 (en) | 2019-12-18 | 2021-06-24 | Ctxt Pty Limited | Compounds |
| CN112999233B (zh) * | 2019-12-19 | 2023-10-20 | 中国医学科学院药物研究所 | 一类来源于赤芍的单萜苷类化合物及其制法和应用 |
| ES3007532T3 (en) * | 2020-03-13 | 2025-03-20 | Hephaistos Pharma | Detoxified lipopolysaccharides (lps), naturally non-toxic lps, and uses thereof |
| WO2021245611A1 (en) | 2020-06-05 | 2021-12-09 | Glaxosmithkline Biologicals Sa | Modified betacoronavirus spike proteins |
| TW202233200A (zh) * | 2020-11-11 | 2022-09-01 | 日商第一三共股份有限公司 | 新穎胺基烷基葡萄胺糖苷4-磷酸衍生物 |
| EP4032547A1 (en) | 2021-01-20 | 2022-07-27 | GlaxoSmithKline Biologicals S.A. | Hsv1 fce derived fragements for the treatment of hsv |
| CA3212345A1 (en) | 2021-03-02 | 2022-09-09 | Glaxosmithkline Intellectual Property Development Limited | Substituted pyridines as dnmt1 inhibitors |
| EP4314060A1 (en) | 2021-03-31 | 2024-02-07 | GlaxoSmithKline Intellectual Property Development Limited | Antigen binding proteins and combinations thereof |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1998050399A1 (en) * | 1997-05-08 | 1998-11-12 | Corixa Corporation | Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4769330A (en) | 1981-12-24 | 1988-09-06 | Health Research, Incorporated | Modified vaccinia virus and methods for making and using the same |
| US4603112A (en) | 1981-12-24 | 1986-07-29 | Health Research, Incorporated | Modified vaccinia virus |
| US4866034A (en) | 1982-05-26 | 1989-09-12 | Ribi Immunochem Research Inc. | Refined detoxified endotoxin |
| US4436727A (en) | 1982-05-26 | 1984-03-13 | Ribi Immunochem Research, Inc. | Refined detoxified endotoxin product |
| US4987237A (en) | 1983-08-26 | 1991-01-22 | Ribi Immunochem Research, Inc. | Derivatives of monophosphoryl lipid A |
| US4844894A (en) | 1984-07-12 | 1989-07-04 | Ribi Immunochem Research Inc. | Method of inhibiting the onset of septicemia and endotoxemia |
| GB8508845D0 (en) | 1985-04-04 | 1985-05-09 | Hoffmann La Roche | Vaccinia dna |
| US4777127A (en) | 1985-09-30 | 1988-10-11 | Labsystems Oy | Human retrovirus-related products and methods of diagnosing and treating conditions associated with said retrovirus |
| US4877611A (en) | 1986-04-15 | 1989-10-31 | Ribi Immunochem Research Inc. | Vaccine containing tumor antigens and adjuvants |
| GB8702816D0 (en) | 1987-02-07 | 1987-03-11 | Al Sumidaie A M K | Obtaining retrovirus-containing fraction |
| WO1989001973A2 (en) | 1987-09-02 | 1989-03-09 | Applied Biotechnology, Inc. | Recombinant pox virus for immunization against tumor-associated antigens |
| EP0324455A3 (en) * | 1988-01-15 | 1991-03-27 | Hans O. Ribi | Novel polymeric immunological adjuvants |
| AP129A (en) | 1988-06-03 | 1991-04-17 | Smithkline Biologicals S A | Expression of retrovirus gag protein eukaryotic cells |
| US4912094B1 (en) | 1988-06-29 | 1994-02-15 | Ribi Immunochem Research Inc. | Modified lipopolysaccharides and process of preparation |
| EP1001032A3 (en) | 1989-08-18 | 2005-02-23 | Chiron Corporation | Recombinant retroviruses delivering vector constructs to target cells |
| AU660325B2 (en) * | 1991-10-11 | 1995-06-22 | Eisai Co. Ltd. | Anti-endotoxin compounds and related molecules and methods |
| AU713040B2 (en) | 1994-07-15 | 1999-11-18 | University Of Iowa Research Foundation, The | Immunomodulatory oligonucleotides |
| US6887483B2 (en) * | 1995-12-01 | 2005-05-03 | University Of Iowa Research Foundation | Non-toxic mutants of pathogenic gram-negative bacteria |
| US5762943A (en) * | 1996-05-14 | 1998-06-09 | Ribi Immunochem Research, Inc. | Methods of treating type I hypersensitivity using monophosphoryl lipid A |
| US5856462A (en) | 1996-09-10 | 1999-01-05 | Hybridon Incorporated | Oligonucleotides having modified CpG dinucleosides |
| US6491919B2 (en) * | 1997-04-01 | 2002-12-10 | Corixa Corporation | Aqueous immunologic adjuvant compostions of monophosphoryl lipid A |
| US6303347B1 (en) * | 1997-05-08 | 2001-10-16 | Corixa Corporation | Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors |
| US6764840B2 (en) * | 1997-05-08 | 2004-07-20 | Corixa Corporation | Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors |
| US6355257B1 (en) | 1997-05-08 | 2002-03-12 | Corixa Corporation | Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors |
| US6368604B1 (en) * | 1997-09-26 | 2002-04-09 | University Of Maryland Biotechnology Institute | Non-pyrogenic derivatives of lipid A |
| GB9727262D0 (en) | 1997-12-24 | 1998-02-25 | Smithkline Beecham Biolog | Vaccine |
| BR9909915A (pt) | 1998-04-09 | 2000-12-26 | Smithkline Beecham Biolog | Composições adjuvantes |
| CA2333578C (en) * | 1998-07-14 | 2010-11-16 | American Cyanamid Company | Adjuvant and vaccine compositions containing monophosphoryl lipid a |
| US6013640A (en) | 1998-08-21 | 2000-01-11 | Ribi Immunochem Research, Inc. | Phosphoglycolipid and methods for its use |
| US6261573B1 (en) * | 1998-10-30 | 2001-07-17 | Avant Immunotherapeutics, Inc. | Immunoadjuvants |
| PT1127137E (pt) * | 1998-11-03 | 2007-12-28 | Staat Nl Verteg Door Min Welzi | Lps com toxicidade reduzida a partir de bactérias gramnegativas modificadas geneticamente |
| AU6896300A (en) * | 1999-08-06 | 2001-03-05 | Corixa Corporation | Vaccines for the treatment of autoimmune disease |
| WO2001034794A1 (en) * | 1999-11-10 | 2001-05-17 | Smithkline Beecham Biologicals S.A. | Casb7434, an antigen over-expressed in colon cancer |
| US6699846B2 (en) * | 2000-03-17 | 2004-03-02 | Corixa Corporation | Mono- and disaccharides for the treatment of nitric oxide related disorders |
-
2001
- 2001-05-18 PT PT01948222T patent/PT1284740E/pt unknown
- 2001-05-18 PL PL365169A patent/PL206832B1/pl not_active IP Right Cessation
- 2001-05-18 KR KR1020027015626A patent/KR100829674B1/ko not_active Expired - Lifetime
- 2001-05-18 DK DK01948222T patent/DK1284740T3/da active
- 2001-05-18 AU AU2001269695A patent/AU2001269695B2/en not_active Expired
- 2001-05-18 CN CNA018114881A patent/CN1606446A/zh active Pending
- 2001-05-18 EP EP08153476A patent/EP2000144A1/en not_active Withdrawn
- 2001-05-18 DE DE60134134T patent/DE60134134D1/de not_active Expired - Lifetime
- 2001-05-18 BR BR0110975-8A patent/BR0110975A/pt not_active IP Right Cessation
- 2001-05-18 IL IL15293501A patent/IL152935A0/xx unknown
- 2001-05-18 JP JP2001586316A patent/JP5004261B2/ja not_active Expired - Lifetime
- 2001-05-18 WO PCT/US2001/016327 patent/WO2001090129A2/en not_active Ceased
- 2001-05-18 CA CA2409221A patent/CA2409221C/en not_active Expired - Lifetime
- 2001-05-18 NZ NZ522755A patent/NZ522755A/en not_active IP Right Cessation
- 2001-05-18 US US09/861,466 patent/US6800613B2/en not_active Expired - Lifetime
- 2001-05-18 HU HU0301815A patent/HU230847B1/hu unknown
- 2001-05-18 AU AU6969501A patent/AU6969501A/xx active Pending
- 2001-05-18 AT AT01948222T patent/ATE395923T1/de active
- 2001-05-18 MX MXPA02011486A patent/MXPA02011486A/es active IP Right Grant
- 2001-05-18 EP EP01948222A patent/EP1284740B1/en not_active Expired - Lifetime
- 2001-05-18 ES ES01948222T patent/ES2305086T3/es not_active Expired - Lifetime
-
2002
- 2002-11-19 IL IL152935A patent/IL152935A/en unknown
- 2002-11-19 NO NO20025543A patent/NO331939B1/no not_active IP Right Cessation
-
2007
- 2007-05-11 AU AU2007202117A patent/AU2007202117B2/en not_active Expired
- 2007-10-08 IL IL186495A patent/IL186495A/en active IP Right Grant
-
2008
- 2008-07-24 CY CY20081100772T patent/CY1108211T1/el unknown
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1998050399A1 (en) * | 1997-05-08 | 1998-11-12 | Corixa Corporation | Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2409221C (en) | Prophylactic and therapeutic treatment of infectious and other diseases with mono- and disaccharide-based compounds | |
| AU2001269695A1 (en) | Prophylactic and therapeutic treatment of infectious, autoimmune and allergic diseases with mono and disaccharide-based compounds | |
| US6911434B2 (en) | Prophylactic and therapeutic treatment of infectious and other diseases with immunoeffector compounds | |
| US8318697B2 (en) | Prophylactic and therapeutic treatment of infectious and other diseases with mono- and disaccharide-based compounds | |
| KR100858947B1 (ko) | 면역효과기 화합물을 사용하는 감염성 질환 및 기타질환의 예방학적 및 치료학적 처치 | |
| US20080119415A1 (en) | Prophylactic and therapeutic treatment of infectious and other diseases with mono- and disaccharide-based compounds | |
| RU2289410C2 (ru) | Профилактика и лечение инфекционных и других заболеваний с помощью соединений, основанных на моно- и дисахаридах | |
| ZA200209438B (en) | Prophylactic and therapeutic treatment of infectious autoimmune and allergic diseases with mono and disaccharide-base compounds. | |
| HK1126398A (en) | Prophylactic and therapeutic treatment of infectious, autoimmune and allergic diseases with mono-and disaccharide-based compounds | |
| RU2288723C2 (ru) | Профилактическое и терапевтическое лечение инфекционных и других заболеваний с помощью иммуноэффективных соединений | |
| HK1102324A (en) | Prophylactic and therapeutic treatment of infectious, autoimmune and allergic diseases with mono and disaccharide-base compounds | |
| HK1078001A (en) | Prophylactic and therapeutic treatment of infectious, autoimmune and allergic diseases with mono and disaccharide-base compounds |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
Patent event date: 20021119 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| PG1501 | Laying open of application | ||
| A201 | Request for examination | ||
| AMND | Amendment | ||
| PA0201 | Request for examination |
Patent event code: PA02012R01D Patent event date: 20060509 Comment text: Request for Examination of Application |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20070530 Patent event code: PE09021S01D |
|
| AMND | Amendment | ||
| E601 | Decision to refuse application | ||
| PE0601 | Decision on rejection of patent |
Patent event date: 20071130 Comment text: Decision to Refuse Application Patent event code: PE06012S01D Patent event date: 20070530 Comment text: Notification of reason for refusal Patent event code: PE06011S01I |
|
| AMND | Amendment | ||
| J201 | Request for trial against refusal decision | ||
| PJ0201 | Trial against decision of rejection |
Patent event date: 20080303 Comment text: Request for Trial against Decision on Refusal Patent event code: PJ02012R01D Patent event date: 20071130 Comment text: Decision to Refuse Application Patent event code: PJ02011S01I Appeal kind category: Appeal against decision to decline refusal Decision date: 20080404 Appeal identifier: 2008101001796 Request date: 20080303 |
|
| PB0901 | Examination by re-examination before a trial |
Comment text: Amendment to Specification, etc. Patent event date: 20080303 Patent event code: PB09011R02I Comment text: Request for Trial against Decision on Refusal Patent event date: 20080303 Patent event code: PB09011R01I Comment text: Amendment to Specification, etc. Patent event date: 20070830 Patent event code: PB09011R02I Comment text: Amendment to Specification, etc. Patent event date: 20060509 Patent event code: PB09011R02I |
|
| B701 | Decision to grant | ||
| PB0701 | Decision of registration after re-examination before a trial |
Patent event date: 20080404 Comment text: Decision to Grant Registration Patent event code: PB07012S01D Patent event date: 20080403 Comment text: Transfer of Trial File for Re-examination before a Trial Patent event code: PB07011S01I |
|
| GRNT | Written decision to grant | ||
| PR0701 | Registration of establishment |
Comment text: Registration of Establishment Patent event date: 20080507 Patent event code: PR07011E01D |
|
| PR1002 | Payment of registration fee |
Payment date: 20080507 End annual number: 3 Start annual number: 1 |
|
| PG1601 | Publication of registration | ||
| PR1001 | Payment of annual fee |
Payment date: 20110428 Start annual number: 4 End annual number: 4 |
|
| PR1001 | Payment of annual fee |
Payment date: 20120427 Start annual number: 5 End annual number: 5 |
|
| FPAY | Annual fee payment |
Payment date: 20130429 Year of fee payment: 6 |
|
| PR1001 | Payment of annual fee |
Payment date: 20130429 Start annual number: 6 End annual number: 6 |
|
| FPAY | Annual fee payment |
Payment date: 20140430 Year of fee payment: 7 |
|
| PR1001 | Payment of annual fee |
Payment date: 20140430 Start annual number: 7 End annual number: 7 |
|
| FPAY | Annual fee payment |
Payment date: 20160330 Year of fee payment: 9 |
|
| PR1001 | Payment of annual fee |
Payment date: 20160330 Start annual number: 9 End annual number: 9 |
|
| FPAY | Annual fee payment |
Payment date: 20180329 Year of fee payment: 11 |
|
| PR1001 | Payment of annual fee |
Payment date: 20180329 Start annual number: 11 End annual number: 11 |
|
| FPAY | Annual fee payment |
Payment date: 20190327 Year of fee payment: 12 |
|
| PR1001 | Payment of annual fee |
Payment date: 20190327 Start annual number: 12 End annual number: 12 |
|
| PR1001 | Payment of annual fee |
Payment date: 20200324 Start annual number: 13 End annual number: 13 |
|
| PR1001 | Payment of annual fee |
Payment date: 20210426 Start annual number: 14 End annual number: 14 |
|
| PC1801 | Expiration of term |
Termination date: 20211118 Termination category: Expiration of duration |